Prolactin (PRL) stimulates the cytoskeletal re-organization and motility of breast cancer cells. During PRL receptor signaling, Vav2 becomes phosphorylated and activated, an event regulated by the serine/threonine kinase Nek3. Given the regulatory role of Vav2, the function of Nek3 in PRL-mediated motility and invasion was examined. Overexpression of Nek3 in Chinese hamster ovary transfectants potentiated cytoskeletal re-organization in response to PRL. In contrast, downregulation of Nek3 expression by small-interfering RNA (siRNA) attenuated PRL-mediated cytoskeletal reorganization, activation of GTPase Rac1, cell migration and invasion of T47D cells. In addition, PRL stimulation induced an interaction between Nek3 and paxillin and significantly increased paxillin serine phosphorylation, whereas Nek3 siRNA-transfected cells showed a marked reduction in paxillin phosphorylation. Analysis of breast tissue microarrays also demonstrated a significant up-regulation of Nek3 expression in malignant versus normal specimens. These data suggest that Nek3 contributes to PRLmediated breast cancer motility through mechanisms involving Rac1 activation and paxillin phosphorylation.
Introduction
Cell migration is essential in normal biological functions such as embryogenesis, immune surveillance and wound repair, and also in pathological processes such as tumor extravasation and metastasis. Migration is a coordinated process that involves rapid changes in the dynamics of actin filaments, together with the formation and disassembly of cell adhesion sites (Brakebusch and Fassler, 2003) . The interplay between the actin cytoskeleton and cell adhesion sites leads to the generation of membrane protrusions and traction forces (DeMali et al., 2003) . External stimuli that control cell migration are sensed by appropriate transmembrane receptors that, upon ligand binding, activate different signaling pathways. Although a large variety of intracellular signaling molecules have been implicated in cell migration, Rho GTPases are pivotal in regulating the biochemical pathways most relevant to migration (Raftopoulou and Hall, 2004) .
As a consequence of the regulatory role in actin polymerization, the formation of lamellipodia and filopodia, and the assembly of focal adhesion complexes, it is not surprising that Rho proteins are also implicated in tumor biology. Modulation of Rho-protein activity can promote the metastasis of tumor cells by disrupting epithelial-sheet organization, increasing cell motility and promoting the degradation of the extracellular matrix (Sahai and Marshall, 2002) . Rat mammary carcinoma cell lines expressing dominant negative mutants of RhoA, Rac1 or Cdc42 implanted into nude mice have been shown to exhibit reduced intravasation into the bloodstream and subsequent metastasis (Bouzahzah et al., 2001) . Although there are no known activating mutations in Rho GTPases, there are numerous examples of overexpression in malignant tissue relative to normal tissue (Sahai and Marshall, 2002) . Of particular note, one study has shown that protein levels of RhoA, Rac1 and Cdc42 were highly elevated in human breast tumors, versus patient-matched normal mammary tissue (Fritz et al., 1999) . In addition to these data, mutations in Rho guanine nucleotide exchange factors (GEFs) have also been described.
The serine/threonine kinase Nek3 has recently been shown to interact with and contribute to the prolactin (PRL)-mediated serine and tyrosine phosphorylation of the RhoGEF Vav2 (Miller et al., 2005) . Nek3 is structurally related to the cell cycle regulatory kinase NIMA (Never In Mitosis A) of Aspergillus nidulans (Tanaka and Nigg, 1999) and displays a typical serine/ threonine protein kinase domain within its N-terminal half (Tanaka and Nigg, 1999) . Vav2 has been shown to activate Rac1, RhoA and Cdc42 (Schuebel et al., 1998; Abe et al., 2000; Liu and Burridge, 2000) , and elimination of 183 amino-terminal residues is sufficient to activate its oncogenic potential (Schuebel et al., 1996) . PRL-mediated activation of Rac1 in Chinese hamster ovary (CHO) cells has been shown to require not only Vav2 but also Nek3 kinase activity. In contrast, overexpression of a kinase-inactivating Nek3 mutant resulted in an inhibition of Rac1 activation (Miller et al., 2005) .
Breast cancer mortality is predominantly due to metastasis. Epidemiological studies identifying PRL as a progression factor for human breast cancer (Holtkamp et al., 1984; Bhatavdekar et al., 1990; Lissoni et al., 1995) have prompted investigators to question whether PRL is involved in the metastatic process. Our lab has shown that PRL can significantly enhance the motility of breast cancer cells in vitro (Maus et al., 1999) . Given the actions of PRL and Nek3, we hypothesized that Nek3 may contribute to the PRL-mediated pathogenesis and motility of human breast cancer. In the present study, we demonstrate that Nek3 participates in PRL-mediated cytoskeletal re-organization, paxillin phosphorylation, cell motility and invasion, and is upregulated in malignant versus normal breast tissue specimens.
Results

PRL stimulates cytoskeletal reorganization of breast cancer cells
Our recent data establishing a role for Nek3 in Vav2-mediated Rac1 activation in response to human PRL stimulation (Miller et al., 2005) and the well-documented actions of Rho family GTPases in cytoskeletal reorganization led us to hypothesize that Nek3 might be involved in PRL-mediated cytoarchitectural changes. We first sought to determine the effects of PRL alone on the actin cytoskeleton of the well-differentiated estrogen receptor (ER)-positive T47D and the poorly differentiated ER-negative MDA-MB231 breast cancer cell lines. To identify alterations in filamentous actin (F-actin), cells in defined medium were stimulated with PRL, fixed and stained with rhodamine-conjugated phalloidin and examined by fluorescent confocal microscopy. PRL stimulation resulted in the appearance of membrane ruffles and stress fibers ( Figure 1a , upper panel) in both cell lines. Moreover, quantitation of rhodaminephalloidin bound to polymerized actin following methanol extraction showed that PRL stimulation induced a statistically significant increase in F-actin formation within 7.5 min in both T47D and MDA-MD 231 cells, and at later time points (Figure 1b) .
Studies from several laboratories have observed correlations between the formation of stress fibers and focal complex formation with the activation of focal adhesion kinase (FAK) and phosphorylation of the scaffolding protein paxillin (Fincham et al., 1995; Ren et al., 2000) . Both FAK and paxillin are localized to focal complexes that provide controlled integration of multiple pathways involved in cytoskeletal re-organization and motility. To determine whether PRL stimulation resulted in the formation of focal complexes in breast cancer cells, T47D and MDA-MB231 cells were labeled with anti-FAK and anti-paxillin antibodies and examined by fluorescent confocal microscopy. In control unstimulated cells, FAK and paxillin immunostaining was predominantly diffuse (Figure 1b , middle and lower panels). In contrast, treatment of T47D and MDA-MB231 cells with PRL at 7.5 min and up to 30 min (Figure 1b and c) resulted in the appearance of highly localized, short adhesions near the leading edge of the cells that transmit strong propulsive tractions and facilitate motility (Beningo et al., 2001) . These data revealed that PRL induced changes in the actin cytoskeleton and the formation of focal adhesion turnover in breast cancer cells.
Nek3 contributes to PRL-mediated cytoskeletal reorganization To investigate whether Nek3 kinase activity contributed to PRL-mediated cytoskeletal re-organization, V5-tagged wild-type (wt) Nek3 was overexpressed in CHO cells, along with wt Vav2 and PRL receptor (PRLr). CHO cells were used for cDNA overexpression studies as they express low or undetectable levels of Nek3, Vav2 and the PRLr (Miller et al., 2005) . Transfection of the PRLr alone into CHO cells, followed by PRL stimulation, resulted in the activation of the Jak2/STAT5 (Brockman et al., 2002) , MAPK (Gao and Horseman, 1999) and Vav/Rac1 (Miller et al., 2005) signaling pathways, demonstrating the responsiveness of CHO transfectants to PRL. Therefore, we hypothesized that overexpression of Nek3 and Vav2 in this system might lead to significant changes in the actin cytoskeleton in response to PRL. Cells were stimulated with PRL and labeled with an anti-V5 antibody and phalloidin. Quantitation of F-actin formation revealed that the expression of PRLr alone and wt Nek3 had relatively minor effects on changes of F-actin in response to PRL stimulation ( To further determine the effects of Nek3 on PRLmediated cytoskeletal re-organization of breast cancer cells, the levels of Nek3 were reduced by knockdown with Nek3 small-interfering RNA (siRNA) or appropriate siRNA control in T47D and MDA-MB231 cells. Western-blot analysis of cells treated with a 100 nM final concentration of Nek3 siRNA showed that an approximate 70% reduction in total Nek3 protein levels could be achieved in both cell lines ( Figure 3a 
Nek3 contributes to PRL-mediated Rac1 activation
The alterations in cell morphology, namely the appearance of membrane ruffles and stress fibers resulting from Nek3 knockdown, suggested that Nek3 might affect Rho GTPase activation. The Rho family of GTPases has been widely demonstrated to control these cellular phenomena (Hall, 1998; Schmitz et al., 2000) . In particular, Rac1 has been implicated in controlling the formation of membrane protrusions and membrane ruffling (Ridley et al., 1992) . To test whether reductions in Nek3 levels resulted in reduced activation of Rac1, T47D and MDA-MB231 cells were treated with Nek3 siRNA in the presence or absence of PRL. Rac1 activity in these cells was assayed by affinity precipitation with Rac1/cdc42 effector-binding domain of PAK3 (p21-activated kinase 3) fused to GST (GST-PBD), which specifically binds activated Rac1-GTP (guanosine triphosphate) (Burbelo et al., 1995) . The amount of Rac1-GTP bound to the GST-PBD beads was determined by Western-blot analysis of Rac1. As early as 7.5 min, and at later time points, of PRL stimulation, Rac1 activity increased as determined by densitometry in both T47D and MDA-MB231 cells transfected with control siRNA (Figure 4a and b) . Interestingly, analysis of independent experiments revealed that Rac1 activity in Nek3 siRNA-transfected T47D cells was reduced significantly after PRL stimulation with an average 3.070.21-fold (X7s.e.m.; Po0.01) reduction in Rac1 activation at 7.5 min over controls (Figure 4a ). MDA-MB231 Nek3 siRNA-transfected cells showed minimal changes, with only under a 1.570.79-fold (X7s.e.m.; Po0.07) reduction in Rac1 activation at 7.5 min over controls (Figure 4b ), thus consistent with the data in Figure 3c . Western-blot analysis of whole-cell lysates (WCL) from both cell lines confirmed an approximate 70% reduction in Nek3 expression of siRNA-treated cells (Figure 4a and b) . These data indicated that Nek3 is significantly involved in PRL-mediated Rac1 activation in T47D cells, while having a lesser impact on this process in the MDA-MB231 cells.
Nek3 modulates the PRL-mediated serine phosphorylation of paxillin To investigate further the potential functions of Nek3 in PRL-mediated effects on the actin cytoskeleton in breast cancer cells, the possibility of Nek3 interaction with paxillin was tested. The multidomain structure of paxillin and the lack of identifiable enzymatic motifs first identified it as an adaptor protein (Turner and Nek3 regulates breast cancer motility SL Miller et al Miller, 1994) . Indeed, since its discovery, several proteins have been identified as binding partners (Brown and Turner, 2004) . To investigate the PRL-dependent association between Nek3 and paxillin proteins, coimmunoprecipitation analyses of T47D WCL were conducted with Nek3 antibodies. As shown in Figure 5a , stimulation of rested T47D cells with PRL resulted in an approximate threefold increase in coprecipitating paxillin at 7.5-30 min.
The ability of PRL to trigger paxillin serine phoshorylation and the role of the Nek3 kinase in this event was then tested. PRL treatment of T47D cells has been shown to result in tyrosine phosphorylation of paxillin (Canbay et al., 1997; Acosta et al., 2003) ; however, there are no reports of changes in paxillin serine/threonine phosphorylation in response to PRL. To evaluate this, untransfected and control siRNAtransfected T47D cells were stimulated with PRL, and anti-paxillin immunoprecipitates were examined for serine phosphorylation (Figure 5b ). Anti-phosphoserine immunoblots revealed an approximate 3.5-fold increase over basal levels of paxillin serine phosphorylation at 7.5, 15 and 30 min time points, with a return to basal levels at 45 min. Strikingly, Nek3 siRNA transfectants showed a loss of paxillin serine phosphorylation in response to PRL (Figure 5b ). To our knowledge, these data represented the first demonstration of paxillin serine phosphorylation in response to PRL and identified the serine/threonine kinase Nek3 as an important kinase contributing to this event. 
Nek3 regulates breast cancer motility and invasion
The association between Nek3 expression levels and the in vitro motility and invasiveness of T47D breast cancer cells was tested by their ability to pass through an uncoated or collagen-I-coated barrier, respectively, in response to PRL. The ability of T47D Nek3 siRNAtransfected cells to migrate through an uncoated 12-mm pore in response to PRL was significantly reduced 24 h after seeding, as compared to control siRNA-transfected cells (Figure 6a ). Parallel to the motility assays, T47D invasion through a Type I collagen matrix was significantly reduced by prior transfection of these cells with Nek3 siRNA (Figure 6b ). It was also noted that treatment with Nek3 siRNA reduced both T47D motility and invasion in response to the fetal bovine serum used as a positive control to a lesser extent, an observation probably attributable to the presence of PRL as well as other chemoattractants found in the serum. Taken together, these findings suggest that Nek3 expression contributes to both T47D migration and invasion.
Nek3 expression is associated with malignant human breast carcinomas
Having noted that the expression of Nek3 can regulate the motility and invasiveness of the T47D line, its expression within primary human breast tissues was examined. To that end, the immunohistochemical expression of Nek3 in a breast tissue microarray (bTMA) comprising core biopsies of normal and hyperplastic tissues, as well as in situ and invasive ductal carcinoma was tested. These studies demonstrated a significant up-regulation of Nek3 expression in malignant versus normal specimens (Figure 7a ). To provide a semiquantitative estimate of Nek3 expression in breast tissues, a labeling index incorporating both label intensity and the percentage of the target tissue labeled was created for each tissue examined. The mean labeling indices of the ductal carcinoma in situ and invasive carcinomas for Nek3 were significantly elevated when compared to normal or hyperplastic epithelium (Figure 7b ) in primary human breast tissues. Thus, these immunohistochemical findings suggest that our studies at the in vitro cellular level, implicating Nek3 expression with motility and invasion, extend to the in vivo tissue level, given the association of Nek3 with the pre-invasive/invasive phenotype.
Discussion
PRL has been implicated in the progression and motility of human breast cancer (Clevenger et al., 2003) ; however, the mechanisms involved in motility signaling pathways have not been fully elucidated. The complementary overexpression and knockdown studies presented GST-PBD was incubated with lysates from PRL-stimulated T47D cells transfected with control or Nek3 siRNA. GTP-bound Rac-1 was 'pulled down' using glutathione Sepharose beads, resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted with anti-Rac1 antibody. Western-blot analysis of WCL with Rac1, actin and Nek3 antibodies was performed to verify equal loading and efficiency of siRNA knockdown. Active Rac1 and total Rac1 expression were measured by densitometry and the amount of Rac1 active form was normalized to total Rac1 (below the blots). Representative of one of three independent experiments is shown. here enabled the determination of the effects of Nek3 on PRL-mediated cytoskeletal re-organization. Overexpression of Vav2 and PRLr resulted in the appearance of membrane ruffles and stress fibers in the presence of PRL. Noteworthy, the coexpression of Vav2 and PRLr in combination with Nek3, in the absence of PRL, augmented these effects to levels seen in PRL-stimulated cells (Figure 2) . Conversely, siRNA knockdown of Nek3 in T47D cells resulted in a significant decrease in F-actin and Rac1 activation (90% maximum reduction at 7.5 min; Figure 4a ) following PRL stimulation as compared to control siRNA transfectants (Figures 3b  and 4a ). Interestingly, siRNA knockdown of Nek3 in MDA-MB231 breast cancer cells did not result in similar effects on the actin cytoskeleton or Rac1 activation (Figures 3c and 4b) . Western-blot analysis showed comparable Nek3 siRNA knockdown efficiency in both T47D, and MDA-MB231 cells (Figure 3a) , eliminating this as a potential reason for this difference in findings. In contrast to T47D, which has been genotyped to the well-differentiated 'luminal' phenotype of breast cancer, MDA-MB231 cells lack expression of E-cadherin and express matrix metalloproteinases, which are properties associated with a more aggressive tumorigenic phenotype, consistent with its 'basaloid' phenotype (Nawrocki et al., 2001; Gordon et al., 2003) . In addition, MDA-MB231 cells have a significantly higher in vitro invasive index (Nawrocki et al., 2001; Gordon et al., 2003) , are metastatic in nude mice (Inoue et al., 1993; Yoneda et al., 1997; Salcedo et al., 2000; Salcedo et al., 2002) and may therefore possess additional mutations that can circumvent Nek3 regulation. Although Western-blot analysis of equal amounts of protein in both cell lines showed no remarkable differences in basal Nek3 expression (Figure 3a) , differences in PRL-mediated kinase activity and consequently phosphorylation of other proteins linked to cancer motility such as Vav2, PI3K, MAPK and paxillin may be significant. Paxillin is a multidomain adaptor that recruits both structural and signaling molecules to focal complexes, where its principal function is to affect efficient cellular migration (Brown and Turner, 2004) . Paxillin is involved in multiple protein-protein interactions and mediates signaling crosstalk through its tyrosine and serine/ Figure 6 Knockdown of Nek3 attenuates the motility and invasion of T47D breast cancer cells. (a) T47D cells transfected with control and Nek3 siRNA were plated in upper transwell chambers and medium containing 500 ng/ml of PRL or 10% FBS was placed in the lower chamber. After 24 h, cells migrating through the transwell filter were stained and fluorimetrically quantified. As a control, cells were plated in parallel on tissue culture dishes to determine the efficiency of siRNA knockdown at the conclusion of each experiment. These cells were lysed and Western-blot analysis was conducted with anti-Nek3 and anti-actin antibodies. (b) For invasion assay, the upper transwell chambers were coated with 120 mg/ml of collagen I and the duration of the experiment was 72 h. Cell lysates for Western-blot analysis were prepared at the conclusion of the experiment. Error bars represent mean7s.e.m., n ¼ 3; as compared to control siRNA transfectants. *Po0.05 and **Po0.005. threonine phosphorylation by activated kinases such as FAK, Src, JNK and p38 (Brown and Turner, 2004) . In the present study, we identify a novel PRL-dependent interaction between the serine/threonine kinase Nek3 and paxillin (Figure 5a ). Although paxillin has been shown to be tyrosine phosphorylated in response to PRL stimulation (Canbay et al., 1997; Montes et al., 2005) , the data presented in this study are the first report of paxillin serine phosphorylation in response to PRL stimulation. Untransfected and control siRNA T47D transfected (Figure 5b and data not shown) showed a significant increase in paxillin serine phosphorylation in the presence of PRL. Moreover, Nek3 siRNA transfectants showed a significant decrease in serine phosphorylation (Figure 5b) , implicating Nek3 as a novel kinase in the regulation of paxillin. Both FAK (Ilic et al., 1995; Roy et al., 2002) and JNK (Huang et al., 2003) have been implicated in cell migration and paxillin phosphorylation. However, our analyses have revealed no interaction between FAK and Nek3, and Nek3 overexpression did not increase JNK activity (data not shown). Therefore, future studies will be aimed at determining if paxillin is a direct substrate of Nek3 and identification of specific serine residues phosphorylated in response to PRL stimulation that may be involved in cell motility.
In the present study, we investigated whether knockdown of Nek3 would affect T47D breast cancer motility and invasion; these studies were not extended to the MDA231 cells, given the modest effect of Nek3 siRNA on Rac1 activation. The motility of Nek3 siRNA T47D transfectants toward PRL and FBS was significantly decreased as compared to control siRNA transfectants (Figure 6a ). In addition, a significant decrease in T47D invasion through a Type I collagen substratum was noted following siRNA-mediated knockdown of Nek3. Although not as invasive as some less well-differentiated cell lines (Nawrocki et al., 2001; Gordon et al., 2003) , T47D cells were obtained from a malignant pleural effusion, suggesting a role for Nek3 in metastatic phenotype in some breast cancer lineages.
The phenotypic effects on the actin cytoskeleton of T47D Nek3 siRNA transfectants (Figure 3b) as well as the downregulation of PRL-mediated Rac1 activation (Figure 4a ) suggest that Nek3 may be acting via Rac1 in part to regulate cell motility. Rac1 activity is regulated by GEFs and Rho GTPase-activating proteins (GAPs), and Vav2 has been shown to stimulate membrane ruffling and motility when overexpressed (Liu and Burridge, 2000; Marignani and Carpenter, 2001) . Additional pathways leading to Rac1 activation also involve paxillin, as paxillin has been shown to participate in the targeting of active Rac1 to the membrane via an interaction with PKL, an ARF-GAP (Turner et al., 1999; Kondo et al., 2000) . Thus, Nek3 contributes to the PRL-mediated phosphorylation of both Vav2 and paxillin and may regulate Rac1 activity through pathways involving both proteins, in a manner that will require additional study.
The actions of Rho GTPases are essential in promoting the formation of cytoskeletal structures that contribute to changes in cell shape and motility; yet no evidence has been found for their activation by gain-of-function mutations. Thus, activation of these proteins in the context of cancer may be due in part to the de-regulation of upstream signals. Our data suggest that PRL-stimulated activation of Nek3 kinase activity may be an important upstream event in the regulation of the Rho GTPase Rac1. The role of Nek3 in the regulation of Rac/Rho activity may take a broader context, as our lab has recently found Nek3 in association with the erbB2 receptor (unpublished data). Given that our anti-Nek3 immunohistochemical analysis of a progression tissue microarray revealed elevated Nek3 expression in premalignant and invasive breast carcinomas (Figure 7) , and that the inhibition of Nek3 activity resulted in the loss of invasive phenotype, our findings would suggest that pharmacologic inhibition of Nek3 may prove a useful strategy in the treatment of breast cancer.
Materials and methods
Cell culture and transient transfections CHO, MDA-231 and T47D cells were maintained as described previously (Rycyzyn and Clevenger, 2002) . Before stimulation with recombinant PRL, cells were rested in defined low-serum medium supplemented with 0.1% bovine serum albumin (Sigma, St Louis, MO, USA) for 24-48 h. CHO cells were transfected as described previously (Rycyzyn and Clevenger, 2002) . Transient transfection of V5-tagged PRLr (human prolactin receptor), wt Vav2 and wt Nek3 cDNA constructs was conducted as described previously (Miller et al., 2005) . For siRNA knockdown experiments, siGENOME SMARTpool reagent consisting of four individual siRNAs targeting the Nek3 gene was purchased from Dharmacon (Lafayette, CO, USA), along with a non-targeting siCONTROL pool. T47D and MDA-MB231 siRNA transfections were conducted using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and X-tremeGENE siRNA reagent (Roche, Nutley, NJ, USA), respectively. All assays with cDNA and siRNA transient transfectants were conducted 48 and 72 h after transfection, respectively.
Immunoprecipitations and Western-blot analysis
To assess in vivo interactions, rested T47D and MDA-MB231 transfectants were stimulated with 250 ng/ml of PRL. Nek3 and paxillin immunoprecipitations of WCL were conducted as described previously (Kline et al., 2001) . Western-blot analysis was conducted with the following primary antibodies: antiactin, 1:1000 (Sigma); anti-Nek3, 1:500; anti-phospho-serine, 1:250 (Biomeda, Burlingame, CA, USA); anti-paxillin, 1:1000 (BD Transduction Labs, Lexington, KY, USA).
Activated Rac-1 and RhoA pull-down assays For Rac1 pull-downs, T47D and MDA-MB231 cells were stimulated for indicated times with 250 ng/ml of PRL and lysed in GST-PBD as described previously (del Pozo et al., 2000) . Rac-1 bound to GST-PBD was labeled with a 1:1000 dilution of the anti-Rac-1 antibody (Upstate Biotechnology, Charlottesville, VA, USA) followed by 1:2500 dilution of antimouse horseradish peroxidase-conjugated secondary antibody (Amersham, Piscataway, NJ, USA). WCL were also immunoblotted for Rac1 as a control.
Immunofluorescence microscopy and F-actin quantitation For fluorescence microscopy, cells were placed in defined medium for 48 h, stimulated with PRL as noted, and fixed and processed for immunofluorescence as described previously Nek3 regulates breast cancer motility SL Miller et al (Clevenger et al., 1990) . Primary antibodies were used in the following dilutions; 1:500 for Nek3, 1:100 for V5 (Invitrogen), 1:50 for rhodamine-conjugated phalloidin (Molecular Probes, Eugene, OR, USA), 1:250 for FAK (BD Transduction Labs) and 1:250 for paxillin (BD Transduction Labs). Fluorescence images were collected on a Zeiss Axiovert microscope with an LSM510 META laser scanning confocal module and Zeiss LSM510 META v3.2 software.
To quantify the cellular F-actin content, a modification of a previously published phalloidin-binding assay was used (Howard and Oresajo, 1985) . At given times after PRL (250 ng/ml) stimulation, cells were washed with phosphate-buffered saline (PBS), fixed with a solution of 3.7% formaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in PBS and permeabilized by incubation with 0.2% Triton X-100 in PBS. A solution containing 1.2 U rhodamine-phalloidin (Molecular Probes, Eugene, OR, USA) in the permeation buffer was then added to cells. After incubation (10 min for T47D cells; 30 min for CHO cells), the wells were washed with PBS, and the bound rhodamine-phalloidin was solubilized by incubation with methanol, in sealed plates, for 16 h at À201C in the dark. The methanol was removed from each well, transferred to fluorometry-compatible 96-well plates and the amount of extracted rhodamine-phalloidin in the supernatants was determined by measuring the rhodamine signal with Synergy HT fluorescence reader (Bio-Tek, Highland Park, VT, USA). Optical examination of cells with an immunofluorescence microscope after the methanol incubation confirmed the complete removal of phalloidin from cells. After methanol removal, cells in the wells were fixed and stained with crystal violet (0.2%) to normalize for cell number. To obtain a more stringent normalization, CHO cells were transfected with pEF-Tracer-V5-His-EGFP as carrier DNA, and the number of CHO transfectants, as green fluorescent protein (GFP)-expressing cells, was counted per each well per condition. Oneway analysis of variance and Bonferroni's post-test analysis was performed for the experiments with T47D and MDA-MB 231 cells, whereas a two-way analysis of variance (ANOVA) and Dunnet's post-test analysis were adopted for the experiments with CHO cells.
Migration and invasion assays T47D cells transfected with control or Nek3 siRNA for 48 h were trypsinized, resuspended in mammary epithelial cell basal medium (MEBM) (Clonetics, Walkersville, MD, USA) and plated in triplicate into upper transwell chambers (Costar, Corning, NY, USA). Transwell chambers were separated by membranes with 12-mm pores and MEBM medium-containing vehicle, 500 ng/ml of PRL or 10% FBS was placed in the lower chamber. After 24 h, the cells on the upper surface of the filter were completely removed by wiping with a cotton swab. The filters were gently washed in PBS and then placed in cell dissociation buffer. Cells released from the filter membrane were centrifuged and resuspended in 200 ml of the Cy-QUANT dye diluted in cell lysis buffer (Molecular Probes). The invasion assay was performed on 12 mm pore polycarbonate transwells coated for 3 h at 371C with a 300 ml solution of 120 mg/ml collagen I (Cohesion Technologies, CA, USA). At 72 h after seeding, cells were harvested and labeled, as above. In order to monitor the efficiency of siRNA knockdown of Nek3, Western-blot analysis of the cell lysates was conducted with anti-Nek3 and anti-GAPDH antibodies. Statistical analysis was generated by a one-way ANOVA analysis followed by Bonferroni's post-test analysis.
Immunohistochemistry and scoring of breast tissue microarrays Immunohistochemistry of bTMA representing 40 cases of benign and malignant pathologies was obtained from the Cooperative Human Tissue Network (CHTN, Philadelphia, PA, USA). Anti-Nek3 polyclonal antibody (1:200) was diluted in DAKO's antibody diluent and applied to the bTMAs according to the DAKO EnVision þ System, Peroxidase diaminobenzidine (DAB) method (Dakocytomation California Inc., Carpinteria, CA, USA) for 1 h at room temperature. Slides were then incubated with anti-rabbit horseradish peroxidase-conjugated secondary antibodies for 30 min at room temperature, followed by DAB þ substrate-chromagen solution for 5 min at room temperature. Slides were counterstained with hematoxylin and mounted.
Visual scoring was conducted by creating virtual slides from the stained bTMAs using an Aperio ScanScope (Aperio Technologies, Vista, CA, USA) and Aperio Imagescope v.6.25 software (Aperio Technologies, Vista, CA, USA). Images of the labeled bTMAs and their corresponding H&E were coordinately read using the synchronization feature of the Aperio software. The bTMAs were scored independently by two investigators and differences in interpretation were resolved by consensus conference. The label intensity was recorded as either dim (1) or bright (2). The percent target labeled was estimated and recorded to the nearest decile as the extent score. Labeling indices incorporating percent target labeled and label intensity were created. The labeling index for each region of interest was the product of the region's extent score and label intensity. Statistical analysis was conducted by determining the mean visual indices for tissues characteristic of normal epithelium, ductal hyperplasia, in situ ductal carcinoma and invasive carcinoma. The mean visual labeling indices of the normal/ hyperplastic epithelium were compared to the indices of the in situ/invasive carcinoma using the unpaired t-test.
